Abiomed (ABMD) Tops Q1 Views; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Join SI Premium – FREE
Abiomed (NASDAQ: ABMD) reported Q1 GAAP EPS of $1.95, which may not compare to the analyst estimate of $0.82. Revenue for the quarter came in at $180 million versus the consensus estimate of $173.27 million.
GUIDANCE:
Abiomed sees FY2019 revenue of $775-790 million, up %15 million versus prior view and the consensus of $768.1 million.
For earnings history and earnings-related data on Abiomed (ABMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Navigator Holdings Ltd. (NVGS) Misses Q3 EPS by 14c
- Cricut Inc. (CRCT) Tops Q3 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
